UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 3)
SCIENTIFIC INDUSTRIES, INC.
---------------------------------------
(Name of issuer)
Common Stock, $0.05 Par Value Per Share
---------------------------------------
(Title of class of securities)
808757 10 8
-----------------------
(CUSIP number)
Warshaw Burstein Cohen Schlesinger & Kuh, LLP
555 Fifth Avenue
New York, New York 10017
(212) 984-7700
Attn: Marshall Lester, Esq.
-----------------------------------------------------------
(Name, address and telephone number of person authorized to
receive notices and communications)
October 30, 2002
-------------------------------------------------------
(Date of event which requires filing of this statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
Page 1 of 1
CUSIP No. 808757 10 8
-----------
--------------------------------------------------------------------------------
1. Names of Reporting Persons. S.S. or I.R.S. Lowell A. Kleiman
Identification Nos. of Above Persons
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (a) [ ]
(See Instructions) (b) [ ]
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Source of Funds (See Instructions) Not Applicable
--------------------------------------------------------------------------------
5. Check if Disclosure of Legal Proceedings is
Required Pursuant to Items 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6. Citizenship or Place of Organization United States of America
--------------------------------------------------------------------------------
Number of Shares 7. Sole Voting Power 139,581
Beneficially
Owned by Each ------------------------------------
Reporting 8. Shared Voting Power
Person With
------------------------------------
9. Sole Dispositive Power 139,581
------------------------------------
10. Shared Dispositive Power
------------------------------------
--------------------------------------------------------------------------------
11. Aggregate Amount Beneficially
Owned by Each Reporting Person 139,581
--------------------------------------------------------------------------------
12. Check if the Aggregate Amount in Row (11) Excludes
Certain Shares (See Instructions) [ ]
--------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11) 14.7%
--------------------------------------------------------------------------------
14. Type of Reporting Person (See Instructions) IN
--------------------------------------------------------------------------------
Page 2 of 2
The following constitutes Amendment No. 2 ("Amendment No. 2") to the
Schedule 13D filed by the undersigned. This Amendment No. 2 amends the Schedule
13D as specifically set forth.
Item 4 is hereby amended to add the following:.
On October 30, 2002, Mr. Kleiman filed a preliminary proxy statement
with the Securities and Exchange Commission in order to solicit proxies for his
reelection to the Board of Directors, for the election of one of the management
nominees, for his shareholder proposal with respect to restrictions on the grant
of options that may be issued to non-employee directors and against the 2002
Stock Option Plan, as more fully set forth therein.
Signature
---------
After reasonable inquiry and to the best of my knowledge and belief,
the undersigned certifies that the information set forth in this statement is
true, complete and correct.
/s/ LOWELL A. KLEIMAN
---------------------------
Lowell A. Kleiman
Date: October 30, 2002
Page 3 of 3